Telix Pharmaceuticals (ASX:TLX): Q3 2026 Imaging Revenue and Pipeline Milestones

Aditi Sarkar

03 November 2026 05:53 PM AEDT

Telix Pharmaceuticals (ASX:TLX): Q3 2026 Imaging Revenue and Pipeline Milestones

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals Limited (ASX:TLX) operates in radiopharmaceutical diagnostic imaging agents and therapeutic development programmes.
Q3 2026 group Revenue reached USD 245 million, up 19% year over year.
Q3 Precision Medicine revenue was USD 201 million, increasing 30% year over year.
Telix reported revised FY26 Research and Development expenditure guidance of USD 240 million to USD 260 million.

Telix Pharmaceuticals Limited (ASX:TLX) develops radiopharmaceutical diagnostic imaging agents and therapeutic development programmes. A closing price of AUD 13.00 was recorded for its shares on 3 November 2026. The company’s 2026 announcements cover trading conditions, operational milestones and the financial context of its activities.

Company Business and Operating Structure

Telix Pharmaceuticals Limited (ASX:TLX) operates through Precision Medicine products and therapeutic radiopharmaceutical programmes. These activities carry distinct commercial characteristics, including variations in customer contracts, product Supply requirements and the timing of revenue recognition. Assessing the business therefore involves more than a headline sales figure: segment disclosures, operating costs and the relevant reporting period also matter.

Precision Medicine includes approved radiopharmaceutical imaging products used in diagnosis and disease assessment, whereas therapeutic candidates remain subject to research, trials and regulatory decisions. The distinction matters financially: revenue from an approved commercial product is not equivalent to expected revenue from a medicine still undergoing clinical development.

2026 Results and Developments

In its 2026 reporting, Telix Pharmaceuticals Limited (ASX:TLX) disclosed that q3 2026 group revenue reached USD 245 million, up 19% year over year. The same disclosure context includes another important measure: q3 Precision Medicine revenue was USD 201 million, increasing 30% year over year. Such figures should be read with their stated basis and currency, particularly when a company reports adjusted and statutory measures or operates across international markets.

Telix issued its September-quarter results on 21 October 2026. The company reported USD 44 million in revenue for its TMS business, compared with USD 47 million in the prior corresponding quarter. The presentation also discussed commercial PSMA imaging products, approval of Pixclara for glioma imaging in the United States and progress in clinical development.

Financial Context and What to Monitor

A further 2026 financial or operational reference is that telix reported revised FY26 research and development expenditure guidance of USD 240 million to USD 260 million. For Telix Pharmaceuticals Limited (ASX:TLX), comparisons between earnings, operating Investment and available resources require care. Reported revenue measures commercial activity, while profit, Cash Flow and contractual commitments capture different dimensions of the business; none is a substitute for the others.

Telix reported that its BiPASS Phase 3 study completed enrolment and announced a proposed Merger with Isotope Technologies Munich during 2026. The October update indicated FY26 revenue tracking toward the upper end of a USD 950 million–USD 970 million guidance range, alongside USD 40 million of other income. Guidance remains forward-looking rather than an achieved FY26 result.

For Telix Pharmaceuticals Limited (ASX:TLX), relevant risks include changes in purchasing patterns, regulatory requirements, reimbursement or customer budgets where applicable, along with execution costs and currency exposure. The importance of each risk depends on the products and markets involved. A market closing price is a trading observation and does not establish the cause of a company’s latest operational results.

Key Insights

Telix Pharmaceuticals Limited (ASX:TLX) enters the subsequent reporting period with investors able to assess its 2026 disclosures across operating activities, financial results and identified milestones. Reported performance should be separated from guidance or objectives, and comparisons should retain the currencies, periods and accounting definitions used in the company’s announcements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.